As of 2024-12-11, the Intrinsic Value of Horizon Therapeutics PLC (HZNP) is
107.31 USD. This HZNP valuation is based on the model Discounted Cash Flows (Growth Exit 5Y).
With the current market price of 116.30 USD, the upside of Horizon Therapeutics PLC is
-7.70%.
The range of the Intrinsic Value is 64.79 - 349.95 USD
107.31 USD
Intrinsic Value
HZNP Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
64.79 - 349.95 |
107.31 |
-7.7% |
| DCF (Growth 10y) |
88.19 - 455.20 |
143.20 |
23.1% |
| DCF (EBITDA 5y) |
31.05 - 55.93 |
33.28 |
-71.4% |
| DCF (EBITDA 10y) |
49.32 - 84.36 |
54.15 |
-53.4% |
| Fair Value |
47.82 - 47.82 |
47.82 |
-58.88% |
| P/E |
31.92 - 54.77 |
41.90 |
-64.0% |
| EV/EBITDA |
22.25 - 68.12 |
31.96 |
-72.5% |
| EPV |
41.85 - 57.47 |
49.66 |
-57.3% |
| DDM - Stable |
24.87 - 169.84 |
97.36 |
-16.3% |
| DDM - Multi |
48.06 - 257.08 |
81.19 |
-30.2% |
HZNP Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
26,631.54 |
| Beta |
-0.28 |
| Outstanding shares (mil) |
228.99 |
| Enterprise Value (mil) |
26,724.37 |
| Market risk premium |
4.60% |
| Cost of Equity |
7.20% |
| Cost of Debt |
5.11% |
| WACC |
6.97% |